Cargando…
Pharmacodynamics of Memantine: An Update
Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer´s disease (AD) in Europe on 17(th) May 2002 and shortly thereafter was also approved by the FDA for use in the same indicatio...
Autores principales: | Rammes, G, Danysz, W, Parsons, C.G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645549/ https://www.ncbi.nlm.nih.gov/pubmed/19305788 http://dx.doi.org/10.2174/157015908783769671 |
Ejemplares similares
-
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013) -
Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009) -
A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers
por: Pope, Laura E., et al.
Publicado: (2012) -
Pharmacokinetics of memantine in rats and mice
por: Beconi, Maria G., et al.
Publicado: (2012) -
The effects of memantine on prepulse inhibition
por: Swerdlow, NR, et al.
Publicado: (2009)